This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to assess the cost-effectiveness of three treatment strategies aimed at achieving remission in patients with early stage rheumatoid arthritis.
Interventions
The three strategies were methotrexate monotherapy with the addition of leflunomide and a switch to methotrexate plus an anti-tumour necrosis factor (TNF) drug when patients experienced an inadequate response to treatment; methotrexate plus leflunomide, followed by methotrexate plus an anti-TNF drug; and methotrexate plus an anti-TNF drug.
Location/setting
Netherlands/out-patient secondary care.
Methods

Analytical approach:
The authors used a validated Markov model to assess the cost-effectiveness of the three interventions (Welsing, et al. 2006 , see 'Other Publications of Related Interest' below for bibliographic details). The time horizon was five years. The authors reported that the analysis was performed, using two perspectives, that of the health care system and that of society.
Effectiveness data:
The clinical and effectiveness data were from two Dutch cohorts: the Nijmegen rheumatoid arthritis inception cohort and the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Patients were selected from these two cohorts if they received one of the three treatment strategies between 2003 and 2008. The baseline characteristics of patients in each of the three groups were matched, based on the initial sample sizes in the two cohorts, using the ratio of one methotrexate patient to one leflunomide patient to three anti-TNF patients. In total, 112 patients were included in the methotrexate group, 47 in the leflunomide group, and 332 in the anti-TNF group. Missing outcome data were estimated using linear intrapolation.
Monetary benefit and utility valuations:
The utility estimates were from a published study, which used the European Quality of life (EQ-5D) questionnaire and British tariffs.
